JPWO2022266162A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022266162A5
JPWO2022266162A5 JP2023577349A JP2023577349A JPWO2022266162A5 JP WO2022266162 A5 JPWO2022266162 A5 JP WO2022266162A5 JP 2023577349 A JP2023577349 A JP 2023577349A JP 2023577349 A JP2023577349 A JP 2023577349A JP WO2022266162 A5 JPWO2022266162 A5 JP WO2022266162A5
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
compound
ceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522718A5 (https=
JP2024522718A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/033523 external-priority patent/WO2022266162A1/en
Publication of JP2024522718A publication Critical patent/JP2024522718A/ja
Publication of JPWO2022266162A5 publication Critical patent/JPWO2022266162A5/ja
Publication of JP2024522718A5 publication Critical patent/JP2024522718A5/ja
Pending legal-status Critical Current

Links

JP2023577349A 2021-06-16 2022-06-15 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物 Pending JP2024522718A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211313P 2021-06-16 2021-06-16
US63/211,313 2021-06-16
PCT/US2022/033523 WO2022266162A1 (en) 2021-06-16 2022-06-15 Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2024522718A JP2024522718A (ja) 2024-06-21
JPWO2022266162A5 true JPWO2022266162A5 (https=) 2025-06-23
JP2024522718A5 JP2024522718A5 (https=) 2025-06-23

Family

ID=82595041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577349A Pending JP2024522718A (ja) 2021-06-16 2022-06-15 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物

Country Status (13)

Country Link
US (2) US11919879B2 (https=)
EP (1) EP4355729A1 (https=)
JP (1) JP2024522718A (https=)
KR (1) KR20240021883A (https=)
CN (1) CN117500785A (https=)
AR (1) AR126159A1 (https=)
AU (1) AU2022291768A1 (https=)
BR (1) BR112023023420A2 (https=)
CA (1) CA3217423A1 (https=)
IL (1) IL308122A (https=)
MX (1) MX2023014197A (https=)
TW (1) TW202317534A (https=)
WO (1) WO2022266162A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11919879B2 (en) * 2021-06-16 2024-03-05 Celgene Corporation Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases
KR20250114133A (ko) * 2022-12-16 2025-07-28 셀진 코포레이션 S1p5의 조정제로서의 헤테로시클릭 화합물
KR20260034665A (ko) 2023-06-30 2026-03-11 사노피 치환된 환형 화합물 및 페닐케톤뇨증 및 기타 아미노산뇨증의 치료 방법
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO167087C (no) 1985-10-25 1991-10-02 Secr Defence Brit Fremgangsmaate for fremstilling av en nitratester.
US5561227A (en) 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
RU2175324C2 (ru) 1995-09-01 2001-10-27 Фармация Энд Апджон Компани Фенилоксазолидиноны, имеющие с-с-связь с 4-8-членными гетероциклическими кольцами
WO2000005214A2 (en) 1998-07-24 2000-02-03 Pfizer Inc. Isoquinolines as urokinase inhibitors
WO2003018549A2 (en) 2001-08-30 2003-03-06 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
RS20050019A (sr) 2002-07-12 2007-09-21 Sanofi - Aventis Pharma Deutschland Gmbh., Heterociklično supstituisani benzoilkarbamidi,postupak za njihovu proizvodnju i njihova primena kao leka
JP4516430B2 (ja) 2002-12-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション 1−(アミノ)インダン並びに(1,2−ジヒドロ−3−アミノ)−ベンゾフラン、ベンゾチオフェン及びインドール
CA2509406C (en) 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
JP2009530389A (ja) * 2006-03-21 2009-08-27 エピックス デラウェア, インコーポレイテッド S1p受容体調節化合物及びその使用
US8962825B2 (en) 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
US20090137549A1 (en) 2006-11-09 2009-05-28 Paul John Edward Novel compounds useful for the treatment of degenerative & inflamatory diseases
WO2010056788A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
ES2427917T3 (es) 2009-02-10 2013-11-04 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
WO2011036889A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
GB201002563D0 (en) 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds
MA34300B1 (fr) 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
US8946230B2 (en) 2010-05-13 2015-02-03 Amgen Inc. Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors
WO2012082947A1 (en) 2010-12-16 2012-06-21 Irm Llc Compounds and compositions as tgr5 agonists
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013169622A1 (en) 2012-05-09 2013-11-14 Zoetis Llc Azetidine derivatives as antiparasitic agents
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲RORc調節劑之芳基磺內醯胺衍生物
BR112015010649A2 (pt) 2012-11-16 2017-07-11 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina
MX2016004934A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
CA2934700A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
FR3017867A1 (fr) * 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
DK3140296T3 (en) 2014-05-07 2018-07-23 Bristol Myers Squibb Co PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES
EP3191453B1 (en) 2014-09-09 2019-10-23 Bristol-Myers Squibb Company Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators
WO2017019540A2 (en) 2015-07-24 2017-02-02 Yale University Inhibitors of n-linked glycosylation and methods using same
HRP20230201T1 (hr) 2015-10-12 2023-03-31 Chong Kun Dang Pharmaceutical Corp. Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste
ES2975689T3 (es) 2016-01-29 2024-07-11 Ono Pharmaceutical Co Derivado de tetrahidronaftaleno
LT3426243T (lt) 2016-03-09 2021-08-10 Raze Therapeutics, Inc. 3-fosfogliceratdehidrogenazės inhibitoriai ir jų panaudojimas
US20200321533A1 (en) 2016-05-24 2020-10-08 President And Fellows Of Harvard College Compounds for organic light emitting diode materials
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
AR110988A1 (es) 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
EP3666770A4 (en) 2017-08-07 2021-04-07 Joint Stock Company "Biocad" NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS
CA3087886A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
US10695334B2 (en) 2018-08-16 2020-06-30 Boehringer Ingelheim International Gmbh Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
JPWO2020071550A1 (ja) 2018-10-04 2021-09-24 京都薬品工業株式会社 Cdk8阻害剤およびその用途
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
CN111484479B (zh) 2019-01-25 2023-06-13 四川科伦博泰生物医药股份有限公司 氮杂环化合物、包含其的药物组合物及其制备方法和用途
CA3143280A1 (en) 2019-07-03 2021-01-07 F. Hoffmann-La Roche Ag Heterocyclic monoacylglycerol lipase (magl) inhibitors
CN114302873A (zh) 2019-08-20 2022-04-08 小野药品工业株式会社 具有s1p5受体激动活性的化合物的盐和晶形
CN112887914A (zh) * 2019-11-30 2021-06-01 深圳市海思半导体有限公司 终端间定位方法及装置
CN111704613B (zh) 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
EP4267117B1 (en) 2020-12-23 2026-04-08 Celgene Corporation Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases
US11919879B2 (en) * 2021-06-16 2024-03-05 Celgene Corporation Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases

Similar Documents

Publication Publication Date Title
JP2024050527A5 (https=)
DK2184279T3 (en) PHARMACEUTICAL PREPARATION CONTAINING AN OPTICAL ACTIVE RELATIONSHIP WITH THE TROMBOPOPIETY INRECEPTOR AGONIST ACTIVITY AND AN INTERMEDIATE PRODUCT THEREOF
RU2007105350A (ru) 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы
JP2005514398A5 (https=)
JP2010540508A5 (https=)
JP2004506611A5 (https=)
WO2001025190A1 (en) Novel diarylamide derivatives and use thereof as medicines
JP2020063289A5 (https=)
JP2003529602A5 (https=)
JP2007532627A5 (https=)
JP2021520415A5 (https=)
JPWO2019213445A5 (https=)
JPWO2022266162A5 (https=)
JPWO2022256434A5 (https=)
JP2008542365A5 (https=)
JPWO2022261383A5 (https=)
JPWO2023016529A5 (https=)
JP2007532625A5 (https=)
JPWO2021071821A5 (https=)
JP2021532183A5 (https=)
JPWO2023072240A5 (https=)
JPWO2023072257A5 (https=)
JPWO2020176654A5 (https=)
JPWO2020247447A5 (https=)
JPWO2023150150A5 (https=)